Work

Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer

Year: 2016

Type: article

Source: Expert Opinion on Investigational Drugs

DOI: 10.1517/13543784.2016.1156857

Authors: S. Percy Ivy, Joyce F. Liu, Jung-Min Lee, Ursula A. Matulonis, Elise C. Kohn

Institutions: National Institutes of Health, National Cancer Institute, Dana-Farber Cancer Institute, Center for Cancer Research

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2274165065

FWCI: 4.862

Cites: 87

Cited by: 58

Related to: 10